Barclays Upgrades UniQure N.V. (QURE) to Overweight Amid Advancements in Huntington's Disease Program

Barclays upgraded its rating for UniQure N.V. (NASDAQ: QURE) from Equal Weight to Overweight and raised the price target to $65, citing a planned Biologics License Application submission as a key catalyst. The firm also highlighted positive preliminary data in another gene therapy trial.

By Laiba Immad Thu, June 25, 2026 at 3:41 PM GMT+3 2 min read · Yahoo Finance · June 25, 2026, 12:41 UTC

Tickers: $QURE

Topics: biotech gene therapy healthcare huntington's disease

Read the full article at Yahoo Finance

More World news

Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC